Australia markets closed

Beximco Pharmaceuticals Limited (R2WA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.43600.0000 (0.00%)
At close: 08:20AM CET
Currency in EUR

Valuation measures4

Market cap (intra-day) 424.32M
Enterprise value 476.26M
Trailing P/E 4.77
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.56
Price/book (mrq)0.52
Enterprise value/revenue 0.01
Enterprise value/EBITDA 0.06

Trading information

Stock price history

Beta (5Y monthly) 0.64
52-week change 33.81%
S&P500 52-week change 327.86%
52-week high 30.5300
52-week low 30.3720
50-day moving average 30.4276
200-day moving average 30.4314

Share statistics

Avg vol (3-month) 31.43k
Avg vol (10-day) 3827
Shares outstanding 5446.11M
Implied shares outstanding 6969.81M
Float 8297.32M
% held by insiders 10.00%
% held by institutions 11.61%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.03
Forward annual dividend yield 46.76%
Trailing annual dividend rate 33.50
Trailing annual dividend yield 3802.75%
5-year average dividend yield 43.89
Payout ratio 432.26%
Dividend date 3N/A
Ex-dividend date 410 Nov 2023
Last split factor 21.1:1
Last split date 323 Nov 2020

Financial highlights

Currency in BDT.

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 11.80%
Operating margin (ttm)19.59%

Management effectiveness

Return on assets (ttm)6.55%
Return on equity (ttm)10.29%

Income statement

Revenue (ttm)41.65B
Revenue per share (ttm)93.37
Quarterly revenue growth (yoy)10.20%
Gross profit (ttm)N/A
EBITDA 9.04B
Net income avi to common (ttm)4.92B
Diluted EPS (ttm)0.0900
Quarterly earnings growth (yoy)15.90%

Balance sheet

Total cash (mrq)1.73B
Total cash per share (mrq)3.88
Total debt (mrq)7.6B
Total debt/equity (mrq)15.50%
Current ratio (mrq)1.63
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)8.18B
Levered free cash flow (ttm)4.27B